Sepideh Ashrafzadeh, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Dermatology | 6 | 2021 | 918 | 1.550 |
Why?
|
Dermatomyositis | 1 | 2023 | 257 | 0.690 |
Why?
|
Urban Health Services | 1 | 2021 | 177 | 0.680 |
Why?
|
Mohs Surgery | 1 | 2021 | 222 | 0.630 |
Why?
|
Rural Health Services | 1 | 2021 | 384 | 0.560 |
Why?
|
Education, Distance | 1 | 2020 | 260 | 0.550 |
Why?
|
Rheumatic Diseases | 1 | 2023 | 648 | 0.530 |
Why?
|
Telemedicine | 3 | 2021 | 3051 | 0.470 |
Why?
|
Skin Diseases | 1 | 2023 | 1093 | 0.470 |
Why?
|
Career Choice | 1 | 2021 | 756 | 0.470 |
Why?
|
Schools, Medical | 1 | 2021 | 878 | 0.460 |
Why?
|
Carcinoma, Squamous Cell | 3 | 2023 | 4021 | 0.420 |
Why?
|
Point-of-Care Systems | 1 | 2021 | 1212 | 0.410 |
Why?
|
Education, Medical | 2 | 2021 | 1725 | 0.390 |
Why?
|
Skin Neoplasms | 3 | 2023 | 5819 | 0.320 |
Why?
|
Evidence-Based Medicine | 2 | 2019 | 3687 | 0.310 |
Why?
|
Pediatrics | 2 | 2020 | 3595 | 0.290 |
Why?
|
Immunotherapy | 1 | 2021 | 4650 | 0.250 |
Why?
|
Health Services Accessibility | 1 | 2021 | 5441 | 0.210 |
Why?
|
Internship and Residency | 1 | 2020 | 5879 | 0.170 |
Why?
|
Electronics | 1 | 2021 | 317 | 0.170 |
Why?
|
Students, Medical | 2 | 2022 | 1930 | 0.150 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 1 | 2023 | 1090 | 0.140 |
Why?
|
Faculty | 1 | 2020 | 383 | 0.140 |
Why?
|
Keratinocytes | 1 | 2020 | 790 | 0.130 |
Why?
|
Uncertainty | 1 | 2020 | 754 | 0.130 |
Why?
|
Evidence-Based Practice | 1 | 2019 | 495 | 0.120 |
Why?
|
Iatrogenic Disease | 1 | 2018 | 539 | 0.120 |
Why?
|
Carcinoma, Basal Cell | 1 | 2020 | 560 | 0.120 |
Why?
|
rho GTP-Binding Proteins | 1 | 2016 | 276 | 0.120 |
Why?
|
Vulnerable Populations | 1 | 2020 | 703 | 0.120 |
Why?
|
Inflammatory Breast Neoplasms | 1 | 2016 | 147 | 0.110 |
Why?
|
Epidemiologic Methods | 1 | 2019 | 1336 | 0.110 |
Why?
|
Aspartic Acid | 1 | 2016 | 576 | 0.110 |
Why?
|
Pandemics | 4 | 2022 | 8641 | 0.110 |
Why?
|
Glutamine | 1 | 2016 | 577 | 0.110 |
Why?
|
Education, Medical, Undergraduate | 1 | 2022 | 1066 | 0.110 |
Why?
|
Medical Errors | 2 | 2018 | 1260 | 0.100 |
Why?
|
Humans | 19 | 2023 | 761423 | 0.100 |
Why?
|
Neoplasms | 1 | 2021 | 22164 | 0.100 |
Why?
|
Biopsy | 1 | 2023 | 6766 | 0.090 |
Why?
|
Safety Management | 1 | 2016 | 760 | 0.090 |
Why?
|
Molecular Targeted Therapy | 1 | 2021 | 2811 | 0.080 |
Why?
|
Skin | 1 | 2023 | 4481 | 0.080 |
Why?
|
Cross-Sectional Studies | 2 | 2021 | 26112 | 0.080 |
Why?
|
Quality Indicators, Health Care | 1 | 2018 | 1792 | 0.080 |
Why?
|
Pilot Projects | 1 | 2020 | 8633 | 0.070 |
Why?
|
Curriculum | 1 | 2020 | 3741 | 0.070 |
Why?
|
Electronic Health Records | 2 | 2021 | 4811 | 0.070 |
Why?
|
Patient Readmission | 1 | 2018 | 3269 | 0.060 |
Why?
|
Models, Statistical | 1 | 2019 | 5077 | 0.060 |
Why?
|
Neoplasm Proteins | 1 | 2016 | 3612 | 0.060 |
Why?
|
United States | 3 | 2021 | 72339 | 0.060 |
Why?
|
Quality Improvement | 1 | 2019 | 3800 | 0.060 |
Why?
|
Research Design | 1 | 2019 | 6178 | 0.050 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3082 | 0.050 |
Why?
|
Practice Guidelines as Topic | 1 | 2019 | 7389 | 0.050 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3202 | 0.050 |
Why?
|
Medicare | 1 | 2020 | 6770 | 0.050 |
Why?
|
Child | 5 | 2021 | 80162 | 0.050 |
Why?
|
Delivery of Health Care | 1 | 2019 | 5335 | 0.050 |
Why?
|
Cohort Studies | 1 | 2021 | 41446 | 0.040 |
Why?
|
Hospitalization | 1 | 2018 | 10718 | 0.040 |
Why?
|
Female | 7 | 2021 | 392581 | 0.040 |
Why?
|
Child, Hospitalized | 1 | 2018 | 182 | 0.030 |
Why?
|
Male | 5 | 2021 | 360736 | 0.030 |
Why?
|
Patient Care | 1 | 2021 | 621 | 0.030 |
Why?
|
Risk Adjustment | 1 | 2018 | 600 | 0.030 |
Why?
|
Random Allocation | 1 | 2018 | 2394 | 0.030 |
Why?
|
Education, Medical, Continuing | 1 | 2019 | 823 | 0.030 |
Why?
|
Neoplasm Invasiveness | 1 | 2021 | 3589 | 0.030 |
Why?
|
Students | 1 | 2021 | 1741 | 0.020 |
Why?
|
Medical Records | 1 | 2016 | 1407 | 0.020 |
Why?
|
Aged | 1 | 2020 | 169235 | 0.020 |
Why?
|
Animals | 1 | 2019 | 168441 | 0.020 |
Why?
|
Neoplasm Staging | 1 | 2021 | 11106 | 0.020 |
Why?
|
Socioeconomic Factors | 1 | 2018 | 7825 | 0.010 |
Why?
|
Child, Preschool | 2 | 2018 | 42254 | 0.010 |
Why?
|
Biomedical Research | 1 | 2019 | 3429 | 0.010 |
Why?
|
Risk Factors | 2 | 2020 | 74167 | 0.010 |
Why?
|
Retrospective Studies | 2 | 2021 | 80582 | 0.010 |
Why?
|
Prognosis | 1 | 2021 | 29620 | 0.010 |
Why?
|
Cell Line, Tumor | 1 | 2016 | 16979 | 0.010 |
Why?
|
Adolescent | 2 | 2018 | 88313 | 0.010 |
Why?
|
Risk Assessment | 1 | 2018 | 23990 | 0.010 |
Why?
|
Time Factors | 1 | 2018 | 39975 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2016 | 26212 | 0.010 |
Why?
|
Infant | 1 | 2016 | 36205 | 0.010 |
Why?
|